Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies
18 déc. 2024 08h18 HE
|
Quoin Pharmaceuticals, Inc.
Clinical Data from First Subject Dosed Twice Daily with QRX003 in Open Label Study Is Positive at Mid-point of TestingSignificant Improvement in Skin Appearance Observed in Pediatric Study after Only...
Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials
16 déc. 2024 10h53 HE
|
Research and Markets
Dublin, Dec. 16, 2024 (GLOBE NEWSWIRE) -- The "Targeted Alpha Therapy Market Size, Drugs Approval, Proprietary Technologies & Clinical Trials Insight 2028" report has been added to ...
Pharming announces positive topline data in pediatric clinical trial of leniolisib
11 déc. 2024 01h00 HE
|
Pharming Group N.V.
Multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Data consistent with the improvements seen in the previously...
H1 Partners with CTI to Streamline Clinical Trial PI and Site Selection for More Inclusive and Efficient Trials
10 déc. 2024 09h00 HE
|
H1
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- H1, on a mission to connect the world to the right doctors, today announced a strategic partnership with CTI Clinical Trial & Consulting Services...
CD40 Targeted Therapies Clinical Trials & Market Opportunity Report 2025, Insight By Company, Country, Indication & Phase
09 déc. 2024 04h48 HE
|
Research and Markets
Dublin, Dec. 09, 2024 (GLOBE NEWSWIRE) -- The "CD40 Targeted Therapies Clinical Trials, Therapeutic Approaches & Market Opportunity Insight 2025" report has been added to ...
Bionical Emas sells EMAS Pharma to Kester Capital following strategic review
09 déc. 2024 02h00 HE
|
Bionical Emas
Bionical Emas, the Early Access Programs and Clinical Trial Supply business, is selling EMAS Pharma to Kester Capital and an incoming executive team.
Clinical Trial Supplies Industry Forecast Report 2025-2033: $4.79 Billion Market Soars as Chronic Disease Incidence Rises Globally
05 déc. 2024 04h31 HE
|
Research and Markets
Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Clinical Trial Supplies Market Global Forecast Report by Services, Phase, Therapeutic Area, End Use, Countries and Company Analysis 2025-2033" report...
Adaptive Research Welcomes Western Radiation Oncology to Expand Community Access to Pioneering Cancer Treatment Trials
04 déc. 2024 08h00 HE
|
Adaptive Research Inc
Western Radiation Oncology has joined Adaptive Research’s growing network of community physician practices.
Understanding & Implementing European Union Clinical Trial Regulation for Drugs & Biologics Training Course (ONLINE LIVE EVENT, December 5, 2024 OR ON-DEMAND)
04 déc. 2024 05h10 HE
|
Research and Markets
Dublin, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The "Understanding & Implementing EU Clinical Trial Regulation" training has been added to ResearchAndMarkets.com's offering. This course covers the...
Priothera to Present Trial in Progress Poster for Mocravimod at 2024 American Society of Hematology (ASH) Annual Meeting
03 déc. 2024 06h00 HE
|
Priothera
Mocravimod is being investigated in a global MO-TRANS Phase 3 study in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation Mocravimod is the only S1P receptor...